India Expected to Review Covishield After Reports of Blood Clots After Vaccination

Last week, Denmark, Norway and Iceland paused rollouts after some recipients reported developing low blood platelet counts and blood clots.

New Delhi: Indian drug regulators are expected to review data on one of the two candidate vaccines in its national COVID-19 vaccination drive after reports that some shot recipients had complained of unusual blood-related illnesses.

The Covishield vaccine candidate is derived from the AZD1222 vaccine developed by researchers at the University of Oxford, and licensed to AstraZeneca Plc, a British-Swedish drugmaker. The Indian company Serum Institute has a contract with AstraZeneca to manufacture Covishield doses and a purchase agreement with the Indian government.

Last week, Denmark, Norway and Iceland, roughly in that order, paused rollouts of AZD1222 doses after some recipients reported developing low blood platelet counts and blood clots. Italy and Austria have also taken note.

Sigurd Hortemo, a doctor with the Norwegian Medicines Agency, told Reuters that they were yet to determine if the three cases reported from their country were linked to the vaccine.

AstraZeneca is yet to comment on the concerns – even as they compound an existing suite of issues the company is already dealing with. Foremost among them is its spat with the EU over supply issues.

News reports

“During the active phase of a COVID-19 infection or post COVID-19, there is inflammation of blood vessels with propensity for clot formation,” Dr C.N. Manjunath, director of the Sri Jayadeva Institute of Cardiovascular Sciences, Bengaluru, told The Hindu in January 2021.

“This can cause heart attacks. However, as the vaccine contains inactivated virus, it is immunogenic” and “produces antibodies but not the inflammation”.

At 9:10 am on March 14, 2021, the Union health ministry website said 29.7 million vaccine doses had been delivered.

N.K. Arora, a member of the National COVID-19 Task Force, told AFP that the body is considering “all adverse events” as well as that there are “no immediate concerns” because the number of such events in India, relative to the population, is “very, very low”.

There have been some news reports of Covishield vaccination followed by, but not necessarily causing, heart attacks:

* Moradabad, January 17

* Ballari, January 18

* Nirmal, January 20

* Shivamogga, January 20

* Bhangrola, January 23

* Ranchi, February 2

During a heart attack, or myocardial infarction, a part of the heart doesn’t receive blood and the heart muscle is damaged. A cardiac arrest happens when the heart suddenly stops beating, and can be brought on by heart attacks.

AEFI reports

According to IndiaSpend, the Ministry of Health and Family Welfare provided only incomplete information about adverse events following immunisation until February 26 – and no reports since then.

At 9:10 am on March 14, 2021, the Union health ministry website said 29.7 million vaccine doses had been delivered.

The last such missive said 46 people had died after being vaccinated and 51 had been hospitalised. IndiaSpend also noted that post mortem procedures had been performed only in some cases and that the government didn’t yet have all the investigation reports (at the time).

According to Arora, who spoke on March 13, there have been “50 to 60” post-vaccination deaths thus far. He also said the government is treating all of them as “coincidental”.

The spate of reports about blood-related issues with the AstraZeneca vaccine are tied to its underlying technology.

Also read: Covaxin Trial’s Info Sheet Skips Mention of Two Rare but Known Risks

Vaccine technology

The Covishield, or AZD1222, vaccine platform uses an adenovirus vector. Researchers take an adenovirus and ‘delete’ some of its genes that allow this virus to replicate. They also add genes to enable the virus to manufacture the spike protein of the novel coronavirus.

When this adenovirus is injected into a body, the virus invades a cell and releases its genes. These genes hijack the cell’s biological machinery and begin producing the spike protein of the novel coronavirus.

Once the spike protein is expressed on the cell’s surface, the body’s immune system takes notice and begins to attack and destroy the affected cells. In the process, the immune response also develops a ‘memory’ of the spike protein.

So the next time some other virus invades the body and has a spike protein – like the novel coronavirus – the immune system could respond in earnest, before an infection takes root.

Scientists around the world have been working on adenovirus vector vaccines for many decades, and in this time have acknowledged one potential problem with this technology.

The vaccine’s efficacy could be affected if a human body has developed resistance, or even immunity, to the adenovirus vector itself. Satyajit Rath, an immunologist at the Indian Institute of Science Education and Research, Pune, told The Hindu that studies are yet to conclusively settle the debate.

However, both Rath and Jacob John, an epidemiologist formerly with Christian Medical College, Vellore, agreed that increasing the vaccine’s dosage could overcome this barrier.

This may be necessary considering AZD1222 is a double-dose vaccine and may have to be administered every year to recipients to ensure people’s bodies maintain a suitable level of resistance to COVID-19 infections.

Such repeated vaccination will also expose the body repeatedly to the adenovirus vector and encourage the body to develop an immune response against it.

Other potential solutions include giving recipients a mix of adenovirus vector vaccines – such as AZD1222, Johnson & Johnson’s jab and Russia’s Sputnik V. This is because these vaccines use different types of adenovirus vectors and elicit different immune responses.

Sputnik V uses different adenovirus vectors – subtypes Ad5 and Ad26 – in each shot, as a result potentially boosting the immune response without allowing the body to become familiar with the vector.

Inactivated virus vaccines like Covaxin, the other candidate vaccine in India’s drive, and mRNA vaccines like Pfizer’s and Moderna’s shots don’t have this problem and can be administered repeatedly.

Kapil Dev Undergoes Angioplasty After Complaining of Chest Pain

“He was evaluated and an emergency coronary angioplasty was performed in the middle of night,” the hospital stated.

New Delhi: India’s first World Cup-winning cricket captain Kapil Dev underwent an angioplasty on Friday after complaining of chest pain and is expected to be discharged in the next couple of days, said the hospital where he is admitted.

The 61-year-old felt uneasy on Thursday following which he was taken to Fortis Escorts Heart Institute emergency department here.

“He was evaluated and an emergency coronary angioplasty was performed in the middle of night,” the hospital stated.

“Currently, he is admitted in ICU and under close supervision of Dr Atul Mathur and his team. Kapil Dev is stable now and he is expected to get discharged in a couple of days.”

Angioplasty is a procedure to open blocked arteries and restore normal blood flow to the heart.

Indian Cricketers Association (ICA) President Ashok Malhotra, a friend of Kapil, earlier told PTI that the iconic cricketer is doing fine.

“He is feeling okay now. I just spoke to his wife (Romi). He was feeling uneasy yesterday. He is undergoing check-ups at a hospital as we speak,” Malhotra, also a former Test player, said.

Unverified reports stated that the 1983 World Cup winner had suffered a heart attack. However, a source close to Kapil said, “The heart attack was a rumour. He is absolutely fine.”

The legendary all-rounder was wished a speedy recovery by many on social media, including India’s current captain Virat Kohli and Sachin Tendulkar among others.


Also wishing him good health was India batsman Shikhar Dhawan and badminton players Saina Nehwal.

Kapil’s former teammate Madan Lal said he has conveyed some of the concern of his well-wishers to the Chandigarh-born legend’s family.


One of India’s greatest cricketers, Kapil played 131 Tests and 225 ODIs.

He is the only player in cricket’s history to claim over 400 wickets (434) and accumulate more than 5000 runs in Tests.

He also served as India’s national coach between 1999 and 2000.

Kapil was inducted into the International Cricket Council’s Hall of Fame in 2010.

Kashmir Needs More Healthcare Now but, Without the Internet, It’s Getting Less

Over 3,000 applications for assistance under the Centre’s Ayushman Bharat scheme have been languishing at the ‘pending’ stage since August 5.

Srinagar: On August 26, a young patient running a high fever was rushed to the out-patient department of S.M.H.S. Hospital in Srinagar. The junior doctor on duty was caught in a predicament when he found the patient’s symptoms didn’t fit any particular diagnosis.

In other circumstances, he would have logged onto his go-to health website and looked for the symptoms there. But with no internet connection and all telephone lines down, he could neither understand the ailment properly nor call a senior doctor to discuss the problem. So he halfheartedly went ahead with his clinical judgement and administered treatment.

Another doctor in the hospital’s casualty department had a similar experience in September.

“Internet access comes handy in such situations,” the second doctor said on condition of anonymity. “I would have researched the problem, … making the diagnosis more accurate.”

“As a doctor, I couldn’t have risked giving [the patient] the wrong drugs. I delayed the treatment and asked him to return the next day. Meanwhile, I took my seniors on board to develop a proper diagnosis.”

The situation was much worse when it involved a surgery.

“There were many patients who went through a preanesthesia checkup before the surgery and required another review from a senior physician,” the second doctor said. “Due to the lack of communication, we couldn’t track down the senior doctors on time. So a staffer would be sent from one department in search of the seniors, who would be in another department at the time. This created a lot of confusion and delayed the surgeries.”

To make matters worse, some of the hospitals ran out of medicines and some equipment during the communications blockade, and couldn’t place new orders.

“Essential kits like Trop T and Venus blood gas kits, which give insights about various diseases, are scarce.”

Postgraduate students were hobbled as well. They said none of them had been able to make any progress on their work since August 5, when the blackout began.

“We need references to write the synopsis. How can we progress when there is no internet?” one scholar at the Government Medical College in Srinagar asked.

The Centre restored internet services in 80 hospitals from the evening of January 1. “The government has also directed restoration of internet broadband services in respect of all other government hospitals as well, where local bottlenecks like connectivity status, billing problems, etc are being worked out and fixed on priority,” a spokesperson’s statement added.

However, hospital staff have found that only the heads of hospitals and selected senior officials have been able to get online. One official at GMC Srinagar said, “There is no access in any ward nor in the libraries of hospitals.”

They share their plight with other hospitals in the valley, as well as non-government initiatives trying to improve access to good and affordable healthcare.

For example, the blockade has set back ‘Save Heart Kashmir’, a programme that three doctors initiated in 2017 to provide cardiac healthcare assistance during emergencies based on WhatsApp messages.

Dr Afaaq Jalali, a senior physician associated with the programme, said that its members had to find other ways to work around the internet barrier.

“When phone connections were restored in Kashmir, our numbers were listed on charts that are pasted at all district, sub-district, primary health centres and other peripheral hospitals. We are available 24*7 to attend to their calls and offer expert advice on how to tackle the emergency,” he said.

Dr Nasir Shamas, also a member of ‘Save Heart Kashmir’, said the blockade forced them to invent and prepare better for such emergencies.

“After August 5, doctors have been trained on all medical emergencies, unlike before, when they were only trained in cardiology. This is done so that if such a scenario arises in the future, we will tackle them efficiently.”

The group currently has around 1,200 members and has catered to over 38,000 patients thus far.

In an ironic but unsurprising example of anti-exceptionalism, government health  health schemes like Ayushman Bharat have also been affected. Many patients avail of benefits from this scheme for dialysis, gall-bladder removal, breathing disorders, cancer care, cardiac stenting and total hip replacement.

The Centre launched the scheme in Jammu and Kashmir in December 2018, since when more than 30,439 patients have registered for an estimated treatment amount of Rs 20.2.

But since August 5, over 3,000 applications for assistance have been languishing at the ‘pending’ stage.

Similar, the state government had conceived of the ‘102’ and ‘108’ toll-free ambulance services to deal with emergencies and to transport referral patients in 2011. By a November 2019 deadline, the government was expected to roll out 416 ambulances.

But according to an official of the National Health Mission, the Jammu and Kashmir government has only procured around 120 critical care ambulances thus far.

“We can’t make them operational without the internet. We need an internet connection to monitor them because they are GPS-fitted ambulances,” the official said.

Rashid Para, the state’s programme manager for emergency care, only said that the vehicles will be made available soon in the new union territory.

The Corporate Media’s War Against Bernie Sanders Is Very Real

A new report offers hard evidence for what you already suspected: MSNBC is riding hard against Bernie.

Supporters of Bernie Sanders have long been accustomed to the nagging feeling that the candidate they champion rarely, if ever, receives a balanced treatment in the mainstream media. Many have also grown used to hearing this impression questioned — characterised as the product of a self-imposed victim complex or a figment of the imagination.

There’s never been any dearth of anecdotal evidence of the media’s systemic bias against Sanders. When MSNBC legal analyst Mimi Rocah declared that Sanders “[makes my] skin crawl . . . [though I] can’t even identify . . . what exactly it is,” she inadvertently summed up the sentiment of generalised but virulent contempt that often characterises the way Sanders and his campaign are discussed on the airwaves and in marquee newspapers. Though there are simply too many cases to list, examples abound of selective reporting of polls, cartoonish torquing of infographics, erasure of facts or figures favourable to Sanders, and outright lying — at the supposedly liberal-leaning MSNBC in particular.

The week of Sanders’s launch, former Hillary Clinton staffer Zerlina Maxwell (introduced by the host simply as an “MSNBC analyst”) was allowed to insist on air that Sanders hadn’t “mentioned race or gender until twenty-three minutes” into his launch speech — a claim that was entirely inaccurate. On another occasion, Chuck Todd discussed a Quinnipiac poll and claimed it showed Sanders had gone down by five points — whereas, in fact, it had shown the exact opposite.

An April 29 segment on the Rachel Maddow Show used blatant cherry-picking of donor data to suggest Sanders had raised “twice as much money from male donors” as female donors — a claim that both flew in the face of the nearly 50-50 gender split among his first-quarter donors and the strong likelihood that he actually had the highest number of female donors overall.

Also read: How Bernie Helped Spark the Teachers’ Revolt

MSNBC, of course, is hardly the only culprit. As Katie Halper documented a few months ago, the New York Times reporter assigned to cover his campaign “consistently paints a negative picture of Sanders’s temperament, history, policies, and political prospects”.

The Washington Post once famously ran 16 negative stories about Sanders in the same number of hours, and its in-house “fact checker,” Glenn Kessler, has himself racked up enough Pinocchios to stuff a landfill with elongated wooden noses.

Nonetheless, a new and systematic look at MSNBC’s recent campaign coverage offers an astonishing empirical snapshot of the media bias facing Sanders in his quest for the Democratic nomination — in this case, from what is ostensibly America’s liberal cable network.

Also read: Bernie’s Old. So What?

Limiting its analysis to coverage of the race’s three leading candidates by the network’s major prime-time shows — The 11th Hour with Brian WilliamsAll In with Chris HayesThe Beat with Ari MelberHardball with Chris MatthewsThe Last Word with Lawrence O’Donnell, and the Rachel Maddow Show — in August and September, the study published by In These Times (and authored by Jacobin’s own Branko Marcetic) should lay to rest once and for all the notion that media bias against the Vermont senator is a figment of his supporters’ imaginations.

Among other things, Sanders received far less coverage than either Joe Biden or Elizabeth:

In its August and September coverage, by total mentions, MSNBC talked about Biden twice as often as Warren and three times as often as Sanders. By number of episodes, 64% of the 240 episodes discussed Biden, 43% discussed Warren and 36% discussed Sanders. A quarter of the episodes only discussed Biden, compared to 5% and 1% that mentioned only Warren or Sanders, respectively.

When the network’s talking heads did mention Sanders, their coverage was most likely to be critical in tone. Negative mentions of Sanders far outstripped those of Biden or Warren, with the latter receiving the highest number of positive mentions:

Of the three candidates, Sanders was least likely to be mentioned positively (12.9% of his mentions) and most likely to be mentioned negatively (20.7%). The remaining two-thirds of his mentions were neutral . . . Warren had the lowest proportion of negative coverage of all three candidates (just 7.9% of all her mentions) and the highest proportion of position mentions (30.6%).

MSNBC’s determination to frame Sanders’s campaign and its prospects in the least favourable light emerge in a number of ways. Deploying familiar tropes about electability and obsessing over poll results, the network’s coverage frequently portrayed Sanders’s proposals as unrealistic and lacking in detail, suggested his campaign was losing steam even when the available evidence indicated otherwise, and boosted demonstrably incorrect claims about the demographic breakdown of his support. For example:

In a later episode, Matthews and The Root’s Johnson claimed African American women were “leaving Bernie” and “breaking for Warren,” even though a Pew Research Center poll that week showed Sanders’ base to be the least white (49%) of the leading four candidates (including Sen. Kamala Harris), Warren’s was whitest (71%), and all four had about 50% women supporters.

With record-breaking fundraising numbers, large rallies, and polls showing a competitive position in crucial early states, Sanders clearly continues to generate enthusiasm from voters. Just don’t expect to hear about it on network TV.

Luke Savage is a staff writer at Jacobin.

This articles was published on Jacobin. Read the original here.  

What We Really Know About Eating Red Meat – and What We Want to Believe

Reducing dietary risk has always been an important nutritional goal, and it would be prudent to continue with what experts have inferred from larger studies.

“Try and avoid red meat. It’s not good for you”

This is advice most non-vegetarians have received – and turns out the scientific data we have available doesn’t support it. Researchers who reviewed various studies in scientific journals have concluded that there is no strong evidence linking red meat with cancers, heart disease and diabetes. A third review, in which scientists examined dietary guidelines for processed and unprocessed red meat, suggests adults can continue to consume them.

Annals of Internal Medicine published the three reviews, along with two more, all of which addressed health outcomes, including cancer, and dietary guidelines concerning the consumption of red meat. An independent group of clinical, nutritional and public health experts called NutriRECS, which specialises in conducting systematic reviews and framing practice guidelines, undertook the exercise.

The first one was concerned with the risk of developing heart disease, lifestyle-related diabetes, high blood pressure and cancer – all conditions that experts have increasingly collected under the umbrella term of ‘cardiometabolic’ illnesses. The researchers looked for clinical trials (published in multiple languages) to compare diets with different quantities of red meat, each differing by a gradient of at least one serving per week for six months or more. There were only a few such trials, and the reviewers found that most of them largely addressed only surrogate outcomes and with small differences in red meat consumption.

So the team concluded that there is “low- to very-low-certainty evidence” that suggests diets with smaller quantities of red meat may have little or no effect on heart or diabetes risks as well as on the incidence of cancer.

Also read: Check Your Vocabulary Before Using ‘Coffee’ and ‘Cancer’ in the Same Sentence

“Our results from the evaluation of randomised trials do not support the recommendations in the United Kingdom, the United States or World Cancer Research Fund guidelines on red-meat intake,” their paper reads. “One could argue, however, that neither do they seriously challenge those recommendations.” In other words, the advice to avoid red meat isn’t founded on what we know.

As the paper added, “Our results highlight the uncertainty regarding causal relationships between red meat consumption and major cardiometabolic and cancer outcomes.”

For the second review, researchers scrutinised observational studies on links between reduced intake and processed meat intake – and cancer mortality and incidence. They concluded that the studies suffered from biases thanks to limitations in the way they assessed people’s diets (including recall bias), how they adjusted for confounding factors and didn’t have enough data for subgroup analyses.

“The possible absolute effects of red and processed meat consumption on cancer mortality and incidence are very small, and the certainty of evidence is low to very low,” the second paper said, much like the first.

The third review evaluated people’s health-related values and preferences, since they determine how much red meat they consume. Its corresponding paper said that – again – the evidence that non-vegetarians “are attached to meat and are unwilling to change this behaviour when faced with potentially undesirable health effects” is of low-certainty.

The fourth review found low-certainty evidence to suggests that omnivores are attached to meat and are more reluctant to change their eating habits, even in the face of well-grounded advice. The fifth offered a set of recommendations on eating red meat and processed meat based on its analysis, including suggesting that adults continue their extant diets containing unprocessed and processed red meat.

Several experts The Wire contacted agreed with the conclusions but not entirely with how the reviewers are interpreting them.

Anura Kurpad, a professor of physiology and nutrition at St John’s Medical College, Bengaluru, and a former president of the Nutrition Society of India, explained that the findings of the new reviews don’t represent reversal of what we know but a “reversal of interpretation and translation”. The point was that the observed negative effects were small enough to translate into “don’t [worry] about this”.

“The finding is still that eating meat has a small risk. The interpretation is that the risk is small enough to ignore.”

Also read: The Fat Lie You’ve Been Told About What’s Hurting Your Heart

According to him, the reviews selected a few studies based on a criterion that is really very strict and more suited to drug trials. “So a lot of observation studies that could also be informative fell through.” They also didn’t compare ‘non-meat eaters’ – or vegetarians – to meat eaters, he said, indicating that the reviews would have been if the they’d looked at lower intakes or even zero intake as the base.

In other words, the reviews’s conclusions are restricted by how the reviewers analysed them, and shouldn’t change the way we think about modifying the amount of red meat we eat. Reducing dietary risk has always been an important nutritional goal, and it would be prudent to continue with what experts have inferred from larger evaluations.

John Ioannidis, a professor of medicine at Stanford University, said, “The numerical results practically are almost identical to what previous meta-analyses have shown: randomised trials show no health benefits and observational studies show no or small health benefits, and the evidence is of low quality.”

The only difference, he continued, is the authors’ conclusion: that the evidence is of low quality and so one needs to be cautious, although he added they “cannot make any strong recommendation”. In contrast, the authors of previous studies have stressed the benefits of cutting back on red meat even if the evidence has been weak.

The methods of the Annals papers “are very rigorous and clearly superior to what was done previously,” according to Ioannidis, and that “their conclusions are appropriate.” Frederic Leroy, a professor at the department of industrial microbiology and food biotechnology at the Vrije Universiteit Brussel, agreed, saying the authors “have performed a very rigorous quality check of the evidence based on the highest scientific standards”.

And while the intentions of previous authors who recommended cutting down red meat may be good, “it would be irresponsible for us to tell people that we know for sure that cutting back on red meat will save their lives.”

In September this year, Leroy had reported that science doesn’t yet support decisions about whether you should reduce your meat intake as well as that doing so could potentially be detrimental to public health, especially in certain vulnerable groups. “Restricting the diet by taking away a valuable nutrient source needs careful planning, nutritional knowledge, and may not be for everyone,” he explained, “especially not when special needs are present, such as in the young and the elderly.”

Also read: Wealthy Indians Must Eat Differently from Those Whose Rights They Defend

Indeed, his study as well as the reviews relate only to the health aspects. “Other issues, such as environmental effects, ideological or religious concerns, and animal welfare aspects require another debate, where context and nuance are also often neglected, unfortunately,” he said.

Most of the evidence that nutritionists have used to argue that people should eat less red meat and processed meat has come from observational studies. In these studies, scientists make note of how much meat the studies’ participants eat and then observe them for many years, recording the incidence of certain chronic diseases, like type-2 diabetes, and the mortality.

But this observation isn’t direct, Most of it comes form participants through self-reported questionnaires, these questionnaires have been known to struggle to capture actual eating behaviour, Leroy said. Plus, health-conscious people in the West who report in these questionnaires are also more physically active, avoid cigarettes and alcohol; and have better access to healthcare. “The observed associations tend to disappear or even reverse when research is done in non-Western settings.”

“This debate offers a nice example of the difference between what we want to believe and what we can really know,” Ioannidis finished.

T.V. Padma is a freelance science journalist.

Democratic Candidate Bernie Sanders Had A Heart Attack, His Team Confirms

In a tweet on Friday, Sanders expressed his gratitude to the staff at the Las Vegas clinic where he was treated and confirmed in a second tweet he was keen to rejoin the campaign trail.

Bernie Sanders, the leading Democratic presidential candidate rushed to hospital earlier this week, had suffered a heart attack, his campaign team confirmed.

The Vermont senator was released from a Nevada hospital on Friday.

The 78-year-old was at a campaign event, on Tuesday, when he experienced chest pains and taken to hospital. Doctors on Friday said that Sanders was diagnosed with a heart attack following a blocked artery.

Sanders was stable as the doctors, Arturo Marchand Jr. and Arjun Gururaj, quickly placed two stents to open up a blocked artery in his heart.

Bernie thanks hospital staff, well-wishers

In a tweet on Friday, Sanders expressed his gratitude to the staff at the Las Vegas clinic where he was treated and confirmed in a second tweet he was keen to rejoin the campaign trail. He said, “After two and a half days in the hospital, I feel great, and after taking a short time off, I look forward to getting back to work.”

He added, “I’m feeling so much better. Thank you for all of the love and warm wishes that you sent me. See you soon on the campaign trail.”

Also read: US Senator Bernie Sanders ‘Deeply Concerned’ About Situation in Kashmir

Health fears allayed

Medical experts were keen to stress that he can return to work later this month, and that the public should not be alarmed.

“There should not be an overreaction to this,” said Dr. Steve Nissen, a heart expert at Cleveland Clinic who did not treat Sanders himself. “If he were my patient, I might ask him to avoid 16-hour days for at least a little bit of time. But there’s absolutely no reason he can’t get back to full activity soon.”

This is the second time in as many months that the oldest presidential candidate has cancelled public appearances. Last month, Sanders backed out of some events in South Carolina because he lost his voice.

The article was originally published on DW. You can read it here


Is Too Much Exercise Bad for You? No.

Even high or above average fitness levels can have a positive effect on your lifespan.

Have you watched a game of hockey being played in your neighbourhood park in the recent or distant past? I doubt it. For a city of more than 20 million people, Delhi has a troubling dearth of decent parks. In fact, there may not be more than a handful. The neighbourhood parks enjoy some bustle in the mornings when people can be seen going about their morning walks, quite a few still attached to their smartphones. The pace is leisurely, few break a sweat, and the parks are deserted for the rest of the day.

Some blame the weather or the air’s (un)cleanliness for not providing the right incentives to play a sport. But it would still be fairer to point the finger at the laid-back attitude of the urban Indian.

In contrast, the average urban Westerner has a pathological interest in sports of all kinds. The British swear by football, New Yorkers can’t stop obsessing about baseball and the average Aussie considers sports a part of life.

But some concerns have been expressed about too much running in the recent past. Some have even been discussing whether “too much exercise” could be bad for the heart. There are reports of sudden deaths among elite marathoners. A higher incidence of atrial fibrillation and coronary artery calcification have also been reported in endurance athletes.

There is also concern over fibrosis being present in the hearts of ultra-runners who have dropped dead. Fibrosis in the heart can be a trigger for lethal arrhythmias that precipitate sudden cardiac death. Intriguingly, Pheidippides – the man who ran the first marathon in antiquity – collapsed soon after delivering his message. It should be noted that he was supposed to be a trained runner.

Two studies – British and Dutch – examined the coronary arteries of long-distance cyclists and runners in CT scans. Both concluded last year that there were more blocks and greater calcification in the arteries of elite athletes than people who did not run or ran a little. On further examination, the researchers observed that although there were more plaques in the coronary arteries of athletes, the plaques by themselves were stable, unlike the unstable plaques seen in the control control.

A stable plaque is dense with a thick cap, and it prevents the plaque from bursting within the artery lumen. The unstable plaque seen more often in sedentary people is soft and full of fatty material. Its cap is thin and fragile, waiting to burst. And once burst, it rapidly triggers clot formation within the artery’s lumen. It is this clot that produces acute coronary syndrome. There is a full blown heart attack if the clot blocks the coronary artery completely, or an unstable angina if the block is partial.

The researchers have speculated that despite having more plaques and calcification, elite athletes are at little risk because the plaques are stable. Currently, there is no explanation as to why there are more plaques in people who have been running or cycling long distance for years. A lot of people were relieved after the two papers were published.

The debate about whether exercising too much can be detrimental continues. Some believe that after a certain point, exercise is no longer healthy and may in fact increase mortality. Others believe that the effect of exercise plateaus after an upper limit: exercising beyond this point will not enhance positive effects. It should not be forgotten that exercise is known to reduce risk of heart disease, hypertension, diabetes and even cancer.

Most, if not all, data on the efficacy of exercise relies on personal observations and questionnaires. Personal documentation can be prone to bias. Many studies also include too few patients who are followed up with for short periods to arrive at former conclusions on the effects of increasing exercise intensity on mortality.

More recently, in October, a large study from the US that included more than 120,000 people was published. The median age was 53 years and the follow-up period was over eight years. The participants were divided into five groups depending on how they performed on the treadmill. The fitness levels were assessed using MET (metabolic equivalents of task) scores achieved on the treadmill. As a result, we have more objective data.

However, the trial was retrospective and not randomised. One MET is energy used when sitting by 40-year-old man weighing 70 kg. It is worth 3.5 ml/min/kg of oxygen consumed. So if you are sitting and reading this article, you are at one MET. It will go up when you exercise. The greater the intensity of your exercise, the higher the MET you achieve. On the treadmill test, you go up to 5 MET in stage 1, 7 MET in stage 2 and to 9 MET in stage 3.

The five groups were:

  1. Elite
  2. High level of cardiorespiratory fitness
  3. Above average fitness
  4. Below average fitness
  5. Low level of cardiorespiratory fitness

The researchers recorded that mortality was lowest among elite participants – 80% lower, in fact, than the ‘low fitness’ group. When compared to the high fitness group, elite fitness participants still had lower mortality by 23%. The researchers concluded that extreme aerobic fitness was associated with the least mortality.

The benefits of increasing aerobic cardiorespiratory fitness were substantial even after adjusting for basal risk factors. There was no evidence of a plateau effect, etc.

The message: ‘if you can get your cardiorespiratory fitness to an elite level, do so’. Even high or above average fitness levels will do because they have an effect on your lifespan. Any level of exercise is better than no exercise, but there is an incremental benefit as fitness levels increase.

The Cleveland data is buttressed by the fact that it has relied on METs obtained on a treadmill test rather than on the relatively less reliable questionnaire. Of course, this may not be the final word on the subject. More large trials with adequate follow-ups will be helpful.

Deepak Natarajan is a cardiologist based in New Delhi.

Discovery of the Gene for a Rare Heart Disease and Why It Matters

Cardiomyopathy, a condition characteristic of showing abnormal heart structure and function without the usual causes of heart disease, is feared for causing sudden death in people younger than 35.

Cardiomyopathy, a condition characteristic of showing abnormal heart structure and function without the usual causes of heart disease, is feared for causing sudden death in people younger than 35.

A nurse defibrillates a patient in a handout photo. REUTERS/Newscom

A nurse defibrillates a patient in a handout photo. Credit: Reuters

Heart disease is the world’s number one killer. In sub-Saharan Africa infections like HIV and TB take the lead but heart diseases such as heart muscle disease (or cardiomyopathy) are a close second as a cause of death. After 20 years of research scientists at the University of Cape Town have identified the mutations in a gene called CDH2, or cadherin 2, that’s responsible for an inherited form of heart muscle disease that affects the right side of the heart in a condition known as cardiomyopathy. The Conversation Africa’s Health and Medicine Editor Candice Bailey spoke to Professor Bongani Mayosi about the significance of the discovery.

What is cardiomyopathy and what do we know about it?

Arrhythmogenic right ventricular cardiomyopathy [ARVC]).

Cardiomyopathy is the technical term for a heart muscle disease. It is particularly feared because it can cause sudden death in people younger than 35, especially during athletic activity.

This is a condition in which the heart’s structure and function is abnormal without the usual causes of heart disease such as high blood pressure, coronary artery disease (which causes a heart attack), valvular heart disease, pericardial disease or congenital heart disease.

We have been studying this form of heart muscle disease called arrhythmogenic right ventricular cardiomyopathy or ARVC. In this disease, the muscle of the right side of the heart is lost and replaced by scar or fat. As a result, the heart is prone to beating irregularly and fast, causing sudden death because blood is not being effectively pumped to the rest of the body.

This is a rare condition that affects one in every 5000 people in the general population. People who participate in elite sport are prone to the condition if they are carriers of a genetic mutation. That’s why there’s a need to screen elite athletes for heart disease to prevent the onset of sudden death while exercising.

It’s an inherited disease. Often several generations of a family will suffer from the same condition.

How is it treated?

Treatment depends on the symptoms of the person affected with the condition. If a person has had syncope (fainting) or has been resuscitated from cardiac arrest, then a cardioverter defibrillator (ICD) needs to be implanted. This is a small device the size of a watch that s implanted under the breast muscle and has a wire that is inserted through the vein into the heart. It provides a shock to the heart in the event of an abnormal heart rhythm to prevent sudden death.

Sometimes an individual’s condition is discovered before symptoms develop, for example during family screening after a relative’s sudden death. In these cases the advice is to avoid activities – such as participation in competitive contact sports – that may predispose the affected individual to sudden death. Some individuals develop heart failure, in which case medication for the treatment of heart failure will be prescribed.

So what is the breakthrough and why is it important?

The importance of the discovery is twofold and has both scientific and clinical impact.

On one hand it helps to clarify the genetic mechanisms underlying ARVC which will assist with future research to develop drugs which could prevent sudden death. On the other hand it makes possible the early detection of many unsuspecting people who are affected by ARVC. In fact, often the diagnostic clinical signs of the disease become clear only after many years. If a subject with ARVC is a carrier of a mutation on the gene CDH2, we will know if other members of his family are genetically affected in a few days and we could immediately start preventive strategies.

This may lead to a reduction of cases of sudden death in patients with this mutation.

What does it mean for cardiovascular studies?

We have found a completely new mechanism to explain the underlying cause of sudden death. This is a seminal observation in biology and offers a new opportunity for a potential target for drugs. This will lead to new treatments being developed.

The finding is also important because it is proof to aspiring young scientists that discovery science is taking place in South Africa. And it’s important that the research was conducted in the public service – this will dispel the perception that the sector isn’t capable of producing such research and results.

The ConversationWe will now conduct large-scale screening activities to establish how common this gene is as well as work on understanding the gene better.

Bongani Mayosi is Dean and Professor of Medicine at the Faculty of Health Science at the University of Cape Town.

This article was originally published on The Conversation. Read the original article.

Long-Term Daily Aspirin Use Linked to Higher Risk of Bleeding in Adults Over 75

“Our findings raise questions about the balance of risk and benefit of long-term daily aspirin use in people aged 75 or over if a proton-pump inhibitor is not co-prescribed.”

“Our findings raise questions about the balance of risk and benefit of long-term daily aspirin use in people aged 75 or over if a proton-pump inhibitor is not co-prescribed.”

A macro shot of aspirin tablets. Credit: Sauligno/Wikimedia Commons, CC BY-SA 3.0

A macro shot of aspirin tablets. Credit: Sauligno/Wikimedia Commons, CC BY-SA 3.0

A new study published online in The Lancet on June 13 has shown that the long-term daily use of aspirin is associated with a higher than expected risk of disabling or fatal bleeding in people aged 75 years and above.

While conceding that short-term aspirin use after a stroke or heart attack has clear benefits, the researchers advised that physicians should prescribe, for patients over 75 who take aspirin on a daily basis, a proton-pump inhibitor (i.e. heartburn drugs; PPI) to reduce the risk of bleeding.

According to the paper, roughly 40-60% of adults aged 75 or above in the US or Europe take daily aspirin or other anti-platelet drugs to prevent heart attacks or stroke. Physicians recommend lifelong treatment with anti-platelet drugs for patients who have previously had a heart attack or stroke. This is considered secondary prevention, a practice followed universally. However, this advice is based on trials done mostly with patients younger than 75, with a follow up of approximately two to four years.

“Previous studies have shown there is a causal link between anti-platelet treatment and upper gastrointestinal bleeding, and although the risk is known to increase with age, estimates on the size of the risk vary widely, there are few data on whether severity of bleeding also increases with age,” a press release from the journal stated.

“We have known for some time that aspirin increases the risk of bleeding for elderly patients,” Peter Rothwell, the study’s lead author, said in the same statement. “But our new study gives us a much clearer understanding of the size of the increased risk and of the severity and consequences of bleeds. Previous studies have shown there is a clear benefit of short-term anti-platelet treatment following a heart attack or stroke. But our findings raise questions about the balance of risk and benefit of long-term daily aspirin use in people aged 75 or over if a proton-pump inhibitor is not co-prescribed. However, suddenly stopping medication is definitely not advised, so patients should always talk to their doctors.”

During the study, Linxin Li, Olivia C. Geraghty, Ziyah Mehta and Rothwell, all researchers from the Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, followed 3,166 patients who had previously had a stroke or heart attack and had been prescribed anti-platelet drugs (mostly aspirin). Half the patients were aged 75 or over at the start of the study. Over the next 10 years, 314 patients (9.9%) were admitted to hospitals for bleeding. The study found that the risk of bleeding, and the risk of fatal or disabling bleeding in particular, increased with age.

For patients under 65 taking aspirin every day, the annual rate of bleeds requiring hospital admission was approximately 1.5%. For patients aged 75-84, the annual rate rose to approximately 3.5% and to 5% for patients aged over 85.

For patients aged under 65, the annual rate of life-threatening or fatal bleeds was less than 0.5%. For patients aged 75-84, the rate rose to approximately 1.5%, and for patients aged 85 or over to nearly 2.5%.

The study also revealed that the outcome of non-fatal bleeds was worse in older ages. The proportion of survivors for whom a bleed resulted in a new or sustained increase in disability rose from 3% (four of 157) for people aged under 75 to 25% (46 of 183) for people aged over 75. Overall, the risk of disabling or fatal bleeding over ten years was 10-times higher at ages 75 years or older compared to younger patients.

Rothwell told this correspondent, “Our population was mostly white British, but there isn’t much evidence from elsewhere to suggest that the bleeding risk would be lower in other ethnic groups.”

As an observational study rather than a randomised trial, the study has a limitation: it is not possible for it to show that the increased risk is entirely caused by aspirin. However, a previous randomised trial has shown that at least half the bleeds occurring due to aspirin are medication-related.

The authors noted that most of the patients in the study were taking aspirin (75 mg enteric coat); a few others were taking clopidogrel. Currently, the study’s findings may not apply to other anti-platelet drugs.

Many patients in the study took aspirin plus clopidogrel in the first few months, which did increase the bleeding risk a little,” Rothwell added. “Previous trials have shown that the bleeding risk on aspirin is similar to that on clopidogrel alone – and so our results are probably reasonably generalisable.”

The findings additionally did not take into account the potential impact of any adverse effects linked to long-term PPI use.

Although the risk of heart attacks and strokes also increases with age, the authors concluded that for patients aged 75 or older, major upper gastrointestinal bleeding as a result of anti-platelet therapy was at least as likely to be as disabling or fatal an event as recurrent ischaemic stroke – if a proton pump inhibitor (PPI) is not co-prescribed.

PPIs could reduce upper gastrointestinal bleeding by 70-90% in patients receiving long-term anti-platelet treatment. However, prescription of PPI is not routine and only about a third of patients in the study were taking them.

While there are some known risks associated with long-term PPI use, the authors concluded that the benefits of PPI use at older ages outweighed the risks. They wanted the guidelines to recommend the co-prescription of PPIs in this age group (following a randomised trial).

“While there is some evidence that long-term PPI use might have some small risks, this study shows that the risk of bleeding without them at older ages is high, and the consequences significant. In other words, these new data should provide reassurance that the benefits of PPI use at older ages will outweigh the risks,” Rothwell said in the journal’s press release.

The paper concluded: “In patients receiving aspirin-based anti-platelet treatment without routine PPI use, the long-term risk of major bleeding is higher and more sustained in older patients in practice than in the younger patients in previous trials, with a substantial risk of disabling or fatal upper gastrointestinal bleeding. Given that half of the major bleeds in patients aged 75 years or older were upper gastrointestinal, the estimated [numbers needed to treat] for routine PPI use to prevent such bleeds is low, and co-prescription should be encouraged.”

In an accompanying comment published in the same issue of The Lancet, Hans-Christoph Diener, of the University Duisburg-Essen, Germany, stated that the first consequence of the study is that the benefit-risk association in long-term anti-platelet therapy should be evaluated every three to five years in patients older than 75 years.

According to him, the second consequence is its support for the need to use PPIs in patients on anti-platelet therapy aged 75 years or older or in patients with a history of gastrointestinal bleeds. “PPIs are underused in patients on anti-platelet therapy, perhaps because the consequences of upper gastrointestinal bleeds were underestimated in elderly patients who were treated with aspirin,” he clarified.

However, Deepak Natarajan, a New Delhi-based cardiologist, cautioned that the researchers failed to “mention that a long-term PPI may increase the risk of chronic kidney damage and cardiovascular events. Ultimately, as per the researchers, you need to treat 25 patients aged 85 years for five years with a PPI to prevent a bleed.”

K.S. Parthasarathy is a former secretary of the Atomic Energy Regulatory Board.